Uniform Controlled Substances Law; revise Schedule I to include certain hemp products.
SB 2187 amends Mississippi’s Schedule I controlled substances list in Section 41-29-113 to add a new category of hemp-derived products: any product derived from the hemp plant that is designed for human ingestion or consumption and is not approved by the U.S. Food and Drug Administration. The bill keeps the existing hemp carve-out for products regulated under Mississippi’s hemp statutes, but narrows that exemption by making clear that unapproved consumable hemp products are controlled substances. The measure also retains and restates Mississippi’s extensive Schedule I listings for opiates, hallucinogens, depressants, stimulants, synthetic cannabinoids, and synthetic cathinones.
In practical terms, the bill would make certain consumable hemp products illegal under Mississippi controlled-substances law unless they have FDA approval, affecting retailers, manufacturers, distributors, and consumers of hemp-derived edibles, beverages, and similar ingestible products. It does not appear to change the broader hemp regulatory framework, but it does create a controlled-substances consequence for a subset of hemp products that are marketed for ingestion. The act is set to take effect on July 1, 2025.
The available context shows no recorded committee debate or votes, so there is no documented floor or committee sentiment in the materials provided. Based on the bill’s structure and caption, the apparent policy direction is a tightening of restrictions on hemp-derived consumables, especially products that may be sold outside the FDA approval process. The bill’s overall tone is regulatory and enforcement-oriented rather than permissive.
The main point of contention is likely the treatment of hemp-derived products that are intended for human consumption but are not FDA approved. Supporters would likely view the bill as a public-safety and drug-control measure aimed at closing a loophole in hemp regulation, while opponents may argue it sweeps in lawful hemp commerce and creates uncertainty for businesses selling consumable hemp products. Another likely issue is the interaction between the controlled-substances code and Mississippi’s separate hemp statutes, especially where products are legal under one framework but newly treated as Schedule I under another.
The bill amends Section 41-29-113 of the Mississippi Code, expanding Schedule I to include unapproved hemp-derived products designed for human ingestion or consumption. This would subject those products to Mississippi’s controlled-substances prohibitions and penalties, while preserving exemptions for hemp regulated under Mississippi’s hemp laws and for FDA-approved hemp-derived consumables and cannabidiol products. The measure primarily affects hemp manufacturers, retailers, distributors, and consumers, and it takes effect July 1, 2025.
No committee transcripts or vote records were provided, so there is no direct evidence of legislative debate or recorded support/opposition in the available materials. The bill’s caption and text suggest a generally restrictive, enforcement-focused approach to hemp-derived consumables, indicating likely support from lawmakers concerned about unregulated intoxicating hemp products and likely resistance from hemp industry stakeholders and advocates for broader hemp commerce.
The central contention is whether hemp-derived products intended for ingestion should be treated as Schedule I controlled substances unless FDA approved. Supporters are likely to emphasize consumer safety, product oversight, and closing loopholes in hemp regulation. Opponents are likely to focus on the impact on lawful hemp businesses, the breadth of the definition, and the tension between state hemp legalization and controlled-substances enforcement. The bill also raises questions about how Mississippi will distinguish regulated hemp products from prohibited consumable hemp items in practice.